The expression of NR5A2 variant 4 has been reported in both ER-positive and ER-negative breast cancer cell lines [20] and our analysis of mRNA sequencing data of TCGA invasive breast cancer cohort found that variant 4 was also the predominantly expressed NR5A2 transcript in primary breast cancers. This evidence concerns the gene NR5A2 and breast carcinoma.